RE:RE:RE:RE:New Press Release - Theratechnologies Announces Dosing of First Patient in Updated Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian CancerI don't disagree that there's every reason to be all over the Montreal site if a patient shows up there that passes all the screening. I'm sure Marsolais would know them fairly well but I'm guessing. Same for other sites -- be all over them best you can. Keeping up with investigators and patients is not outsourced to a CRO, they are just the data collector used by the investigative sites real-time, but you probably know that. It seemed clear from past calls they have the in-house trial team and some outside advisors on the trial and they've spoken about regular meetings with investigators and such. I think it may have been mentioned Marsolais, in the dosage and followup part, was pretty much in constant contact with them all. You can bet given the much smaller size he'll be all over it. This is his baby in many ways, with his name on the research papers.